Introduction
CCAAT Enhancer Binding Protein α (C/EBPα) functions as a key regulator of granulocytopoiesis 1 . C/EBPα is activated in early myeloid precursors and directs them to granulocytic maturation 2, 3 . Loss of C/EBPα functions has been linked to leukemogenesis, suggesting an important role for C/EBPα as a tumor suppressor 4, 5 .
In acute myeloid leukemia (AML), C/EBPα is deregulated by various mechanisms including its own mutations 6 . Mutations in the CEBPA gene are reported for about 10% of all AMLs 7 . The mutations of CEBPA are point mutations in the C-terminal basic region-leucine zipper domain and frame shift mutations in the N-terminal domain. The CEBPA N-terminal mutation results in a shorter form of C/EBPα, C/EBPα-p30, which fails to induce differentiation and exhibits a dominant-negative function over C/EBPα-p42 4, 5 . A conditional silencing of C/EBPα in mice shows a selective block in the differentiation of granulocytes 8 .
MicroRNAs (miRNAs) are a group of gene regulators and play important roles in biologic processes such as cell proliferation and differentiation, and apoptosis, all of which are frequently affected in cancer.
Growing number of studies demonstrate that the deregulation of miRNAs is associated with the development of cancer including leukemia 9, 10 . Former studies have demonstrated the regulation of specific miRNAs by C/EBPα. Fazi et al. first identified miR-223 as a direct target of C/EBPα. The C/EBPα-induced upregulation of miR-223 leads to granulopoiesis 11 . Moreover, recent studies from our group show a direct regulation of miR-223 and miR-34a by C/EBPα in normal granulopoiesis and emphasize that C/EBPα acts as a tumor suppressor gene via transactivation of these miRNAs 12, 13 . Furthermore, in AML where the expression of C/EBPα is deregulated, the transactivation of both miRNAs is inhibited and myeloid differentiation is blocked [11] [12] [13] .
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Some other studies describe a function of miR-30c in several cancers like bladder 16 tumor, breast cancer 17 and endometrial cancer 18 . In breast cancer and AML with NPM1 mutations, miR-30c functions like a tumor suppressor 19, 20 . There has been no report, which shows any specific function of miR-30c in granulopoiesis and AML independent of NPM1 mutations.
In the present study, we firstly investigated the role of miR-30c in C/EBPα-induced granulocytic differentiation and AML, in particular, normal karyotype AML with CEBPA mutations. We identified the miR-30c gene as a new direct C/EBPα target. A in silico analysis identified NOTCH1 as a putative target of miR-30c and with a luciferase assay we could show that NOTCH1 is directly regulated by miR-30c. Here we show that an induction of C/EBPα-p42 but not of C/EBPα-p30 leads to an increased miR-30c expression and consequently downregulation of the direct target gene NOTCH1. A block of miR-30c by LNAs prevents the C/EBPα-induced repression of Notch1 protein expression, thus, miR-30c is necessary for C/EBPα to block Notch1. Furthermore, a block of miR-30c leads to reduced CD11b expression during granulopoiesis.
Our study supports a new molecular network involving miR-30c, C/EBPα, and Notch1 as major components of the granulocyte differentiation program.
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Methods
Human cell samples from AML patients
AML patient samples were obtained from University Hospital Münster (Münster, Germany), University Hospital Leipzig (Leipzig, Germany) and from Munich Leukemia Laboratory (MLL, Munich, Germany). The study protocols used for AML patient sample collection were approved by the ethics committees of the participating centers. All patients provided written informed consent in accordance with the Declaration of Helsinki. All samples were analyzed by cytogenetic and molecular genetic analysis.
Hematopoietic CD34+ cells were isolated from leukapherisates using CD34+ selection kit (Miltenyi Biotec). Percentage of cells positive for CD34 antigen was analyzed by FACS analysis using PE-conjugated mouse anti-human CD34 antibody (BD Bioscience) and found to be around 93%.
Cell cultures
293T cells for lentivirus production were cultivated in DMEM medium complemented with 10% heat inactivated fetal bovine serum (FBS) and 1% penicillin-streptomycin.
K562-C/EBPα-p42-ER, K562-C/EBPα-p30-ER, and K562-ER cells were maintained in RPMI 1640 without phenol red supplemented with 10% charcoal-treated FBS, 1% were cultivated at 2.5x 10 5 /ml in IMDM supplemented with 10% FBS, 50ng/µl stem cell factor (SCF), 50ng/µl FLT3-Ligand and 50ng/µl Interleukin-6 (IL-6). IL-6 was replaced with 50ng/µl Interleukin-3 (IL-3) after the first three days of culture.
Granulocytic differentiation was induced with 100ng/µl G-CSF 22 . Treatment of the cells was done every third day of the experiment process.
Inducible C/EBPα knockout mice
The adult C/EBPaflox/flox; Mx-Cre conditional knockout mice 8 were treated with polyinosinic-polycytidylic acid (poly I:C) to induce Mx-Cre recombinase mediated excision of C/EBPα in hematopoietic cells. Briefly, 600µg Poly I:C was given by intraperitoneal injection every alternate day for a total of five injections and mice were sacrificed two weeks after the last injection. Bone marrow was harvested and stained for myeloid precursors to confirm the block on myeloid differentiation. We sorted for 
Immunoblot analyses
Immunoblot analyses were performed as previously described 12 . For Notch1 protein detection a rabbit monoclonal antibody anti-Notch1 (Epitomics) and for Trib2 protein detection the mouse monoclonal antibody anti-Trib2 (sc-100878; Santa Cruz Biotechnology) were used. The polyclonal rabbit anti-GAPDH (sc-25778) antibody was used for normalization. The Immunoreactivity was determined using an enhanced chemiluminescence (ECL) method (Amersham Biosciences) as per the manufacturer´s instructions. The band intensities were quantified using ImageJ software (National Institutes of Health).
DNA constructs and cloning
The C/EBPα expressing lentiviral vector was prepared by digesting pBluescript-C/EBPα with BamHI and XhoI, repairing ends with DNA polymerase I (Klenow fragment) and ligating into the XbaI digested pCDH1-MCS1-EF1-copGFP plasmid (System Biosciences).
The wild-type C/EBPα-pcDNA3 construct as well as the control vector pcDNA3 have been published before 4 .
For the NOTCH1 3' untranslated region (UTR) luciferase vector, the UTR sequence was amplified from human genomic DNA and inserted into the unique XbaI restriction site 3' to the luciferase gene in the pGL3-promoter plasmid (Promega). The primer sequences have been reported before 23 . The pGL3 mutant NOTCH1 3'UTR vector was generated using QuikChange II XL Site-Directed Mutagenesis kit (Stratagene) according to the manufacturer's instructions. For the miR-30c-expression vector, the mature miR-30c sequence was cloned into the pcDNA™6.2-GW/EmGFP-miR plasmid using the BLOCK-iT™ Pol II miR RNAi Expression Vector Kit (Invitrogen).
All primer sequences are provided in supplemental Table1. The correct assembly of the vectors was verified by sequencing.
Lentiviral infection
293T cells were co-transfected using calcium-phosphate-transfection with either empty vector or C/EBPα-pCDH1-MCS1-EF1-copGFP along with the packaging plasmids pVSVG, pRSV-Rev and pMDL g/pRRE. Virus containing supernatants were collected at 24 and 48 hours after transfection, filtered through 0.45 µm filter and centrifuged at 35,000 rpm for two hours at 4°C in a Sorvall WX ultracentrifuge using a TH-641 rotor. Pellets were resuspended in PBS and stored at -80°C. Lentiviral transduction of K562 cells was performed in 6-well culture dishes for two consecutive days.
Chromatin immunoprecipitation
The chromatin immunoprecipitation assay was performed using ChIP-IT ® Express
Enzymatic 
Luciferase reporter assay
To test whether miR-30c directly targets Notch1, MV4-11 cells were transiently transfected with 0.7 µg of each reporter construct (wild-type or mutant NOTCH1 3'UTR), 0.1 µg of Renilla construct and 1.4 µg pCDNA6.2-emGFP-miR-30c or control plasmid by lipofectamine LTX (Invitrogene) as described by the manufacturer. Firefly luciferase activities from the promoter constructs and Renilla luciferase activity from the internal control plasmid were determined 24 hours after transfection using the Dual-Luciferase Reporter Assay System (Promega). Values were normalized by using Renilla luciferase.
Cell differentiation
Cell differentiation was assessed by FACS analysis using PE-conjugated mouse antihuman CD11b antibody (BD Biosciences) as previously described 24 .
Statistical analysis
We used the Student t test to determine the statistical significance of experimental results. A p-value of 0.05 or less was considered significant. The results were represented as the mean ± SD from 3 independent experiments.
Results
C/EBPα-p42 upregulates miR-30c during granulopoiesis
Past studies have shown a high expression of miR-30c in granulocytes 14, 15 . To assess the role of miR-30c during granulopoiesis, we analyzed its expression upon lentiviral transduction of C/EBPα in K562 cells. With a quantitative real-time polymerase chain reaction (Q-RT-PCR) in K562 we observed a high expression level of miR-30c ( Figure 1A ). We also analyzed the expression levels of miR-223, a miRNA that has been reported to be upregulated during granulopoiesis 11, 12 . As . CEBPA N-terminal frame-shift mutation is responsible for premature termination of the full length C/EBPα-p42 isoform while keeping the truncated C/EBPα-p30 protein intact 4 and is associated with AML in mice 19 . Therefore, we investigated if the p30 mutant form mediates miR-30c expression. We observed that treatment of K562-C/EBPα-p30ER cells with β -estradiol fails to show any increase in miR-30c expression ( Figure   1C ). We did not observe any change in miR-30c expression in the control cell line K562-ER ( Figure 1D ). These data suggest that upregulation of miR-30c during granulocytic differentiation is a specific function of the C/EBPα-p42 isoform. To further understand the regulation of miR-30c in granulocytic differentiation, we analyzed the expression during retinoic acid (RA)-induced differentiation of U937 cells. We observed that RA is able to induce the expression of miR-30c ( Figure 1E ).
To assess the role of miR-30c during granulopoiesis, we analyzed its expression during differentiation of primary human CD34+ hematopoietic progenitor cells obtained from leukapheresis. CD34+ cells were cultured in the presence of a sequential cytokine cocktail that has been shown to induce granulopoiesis 22 . We observed granulocytic differentiation of CD34+ cells as evaluated by expression of granulocytic markers 13 . miR-30c expression was analyzed by RT-PCR, 7 and 14 days after induction of differentiation. We observed a gradual increase of miR-30c expression during granulocytic differentiation ( Figure 1F ).
miR-30c is downregulated in normal karyotype AML patient samples with
CEBPA mutations
Since miR-30c is regulated by the C/EBPα-p42 isoform and the mutant C/EBPα-p30 fails to regulate it, we hypothesized that this miRNA could be downregulated in AML patient samples, especially in normal karyotype AML with CEBPA mutations. Recent studies found CEBPA mutations predominantly in cytogenetically normal AML (CN-AML) 4, 5 , having been reported in 13% to 19 % of young AML patients 4, 25, 26 . To understand its regulation in AML, the expression levels of miR-30c were quantified in diagnostic samples of AML patients. In general, miR-30c levels were substantially repressed in AML samples compared to healthy donors (Figure 2A ). In particular, we found that miR-30c is slightly lower expressed in normal karyotype AML patient samples with monoallelic CEBPA mutations and strikingly low expressed in AML Figure 3C ).
miR-30c is a direct target of C/EBPα
Next we investigated whether C/EBPα-p42 directly binds to miR-30c. We found several putative C/EBPα binding sites in the minimal promoter regions upstream of miR-30c-1, miR-30c-1 host gene NFYC and miR-30c-2. Therefore we performed chromatin immunoprecipitation (ChIP) experiments in K562-C/EBPα-p42ER cells.
The cells were treated for four hours with β -estradiol, and the chromatin fragments were immunoprecipitated with an anti-C/EBPα antibody. The DNA fragments were analyzed with specific primers for the indicated regions of the miR-30c regulatory region ( Figure 4A ). We could observe an enrichment of DNA from all predicted C/EBPα binding sites ( Figure 4B ) compared to the IgG control. Furthermore, we
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could see a changing in the binding affinity of chromatin after C/EBPα induction in K562 cells compared to the control, as measured by Q-RT-PCR ( Figure 4C ). These data suggest that C/EBPα-p42 interacts with the miR-30c regulatory region.
NOTCH1 is a direct target of miR-30c
Using TargetScanHuman 6.0 (www.targetscan.org) prediction algorithm, we identified a putative binding site of miR-30c in the 3' untranslated region (UTR) region of NOTCH1 which is highly conserved in human, mice, rat, and dog ( Figure 5A,B) . We hypothesized that NOTCH1 is the key target of miR-30c.
Since C/EBPα-p42 directly regulates miR-30c ( Figure 1B, 4) and NOTCH1 is a putative target of miR-30c ( Figure 5A ), we analyzed the potential of C/EBPα-p42 protein in regulating Notch1 protein. C/EBPα-p42 function in K562 cells is able to cause suppression of Notch1 protein, although its transcript levels were unaltered ( Figure 5C ) after C/EBPα induction. We found an inverse correlation of miR-30c expression ( Figure 1B ) and Notch1 protein level ( Figure 5C ). The mutant C/EBPα (C/EBPα-p30) fails to downregulate Notch1 protein level ( Figure 5D ).
Recent works had shown that TRIB2 is a transcriptional target of NOTCH1
27 which directly inhibits the function of C/EBPα-p42 and causes AML in mice 28, 29 . Therefore, we examine the protein expression of Trib2 upon C/EBPα induction in K562-C/EBPα-p42ER cells. We observed a decrease of Trib2 protein after six hours. The decrease of Trib2 is temporally displaced to the downregulation of Notch1 which indicates TRIB2 as a transcriptional target of NOTCH1 ( Figure 5E ). These data hint that C/EBPα-p42 plays a critical role in the regulation of Notch1 protein level during granulocytic differentiation. To validate NOTCH1 as a target of miR-30c, we analyzed Notch1 protein levels after overexpression of miR-30c in K562 cells. We observed reduced Notch1 protein levels ( Figure 5F ). Furthermore, we detected a decrease of Figure 5G ).
To test whether NOTCH1 is a direct target of miR-30c, we conducted luciferase reporter assays in MV4-11 cells, which do not express miR-30c 14 , with a construct containing 3'UTR of the NOTCH1 gene with the putative binding site (Notch1 3'UTR WT, Figure 5H ). We also generated a control vector containing a mutated miR-30c binding site (Notch1 3'UTR mut, Figure 5H ). These reporter constructs were cotransfected with either pcDNA6.2-EmGFP-miR-30c or control vector. Relative luciferase activity was significantly decreased 24 hours after miR-30c transfection compared to transfection with the control vector pcDNA6.2-EmGFP indicating that miR-30c targets Notch1 mRNA via a direct interaction with the 3'UTR. The vector containing the mutated miR-30c binding site shows no reduced luciferase activity ( Figure 5I ), indicate a miR-30c-specific inhibition of Notch1.
miR-30c is necessary for C/EBPα to block Notch1 and to induce myeloid differentiation
Since miR-30c is directly regulated by C/EBPα-p42 (Figure1B, 4) and directly targets Notch1 ( Figure 5 ) we hypothesized that C/EBPα blocks Notch1 protein expression through upregulation of miR-30c and that this is necessary for granulocytic differentiation. Blocking of miR-30c with LNA oligonucleotides in K562 cells led to an increase of Notch1 protein expression. Moreover, the suppression of Notch1 caused by ectopic expression of C/EBPα was substantially alleviated by blocking miR-30c
( Figure 6A ). Collectively, these data suggests that miR-30c is necessary for C/EBPα to block Notch1 protein expression during granulocytic differentiation.
A block of miR-30c by LNA oligonucleotides in K562-C/EBPα-p42ER cells induced with β -estradiol to undergo myeloid differentiation, leads to reduced number of Figure 6B ). These data illustrates that miR-30c is necessary for C/EBPα to induce myeloid differentiation.
Discussion
The transcription factor C/EBPα is a master regulator in the normal hematopoiesis 30 .
Previous studies have shown that C/EBPα acts via regulation of specific miRNAs.
Fazi et al. first identified miR-223 as a direct target of C/EBPα
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. The C/EBPα-mediated upregulation of miR-223 leads to granulocytic differentiation 11, 12 . Recent studies from our group show a direct regulation of miR-223 and miR-34a by C/EBPα in normal granulopoiesis. C/EBPα transactivates these miRNAs and acts as a tumor suppressor gene in this way 12, 13 . Moreover, in AML where C/EBPα is deregulated, the transactivation of miR-34a and miR-223 is inhibited and myeloid differentiation is blocked [11] [12] [13] .
In the present study, we identified miR-30c gene as a novel direct target of C/EBPα- In the current study, we firstly show that NOTCH1 is a crucial direct target gene of miR-30c. We identified a conserved binding site of miR-30c in the 3'UTR of Notch1 using luciferase reporter assay in MV4-11 cells ( Figure 5 ). NOTCH1 encodes a membrane receptor and transcriptional regulator, which plays a critical role in T-cell development 32 . Recent studies have shown that an activation of NOTCH1 signaling either by treatment with Notch ligands or by enforced expression of constitutively For personal use only. on April 15, 2017. by guest www.bloodjournal.org From activated NOTCH1 gene, resulted in a inhibition of granulocytic differentiation and preservation of a more immature phenotype in the myeloid cell lines 32D and HL-60, and in primary murine and human myeloid progenitor cells [33] [34] [35] [36] . Notch signaling can play both oncogenic and tumor-suppressor roles in solid tumors, in the hematopoietic system it is exclusively oncogenic, notably in T-cell ALL, a disease characterized by Notch1-activating mutations 37 . Our data show firstly that an induction of C/EBPα-p42 is able to downregulate the protein but not the mRNA level of Notch1 ( Figure 5C ).
miR-30c expression ( Figure 1B ) and Notch1 protein ( Figure 5C ) show an inverse correlation. C/EBPα-p30 fails to downregulate the Notch1 protein and mRNA level ( Figure 5D ). A specific subset of human AMLs associated with impaired C/EBPα function also shows a high Trib2 expression 27, 28 . Because Wouters et al. identified
TRIB2 as a direct transcriptional target of oncogenic NOTCH1 27 which functionally inactivates C/EBPα by causing its degradation 28, 29 , we also analyzed the Trib2 protein level by C/EBPα-p42 overexpression and observed a decrease ( Figure 5F ).
Our data suggest that C/EBPα-p42 plays a critical role in the regulation of Notch1 protein level during granulocytic differentiation. An inhibition of miR-30c with LNA oligonucleotides in K562 cells leads to an increase of Notch1 protein level ( Figure   6A ) and to reduced number of CD11b positive cells during myeloid differentiation ( Figure 6B ). Collectively, our study indicates that miR-30c is necessary for C/EBPα to block Notch1 protein and induce myeloid differentiation. A recent study shows that a block of miR-30 by antisense oligonucleotides enhances self-renewal, tumor regeneration and metastasis in differentiated breast cancer cells 19 . Even though miR30c has been shown to be involved in AML with NPM1 mutations 19 and its high expression levels in granulocytes 14, 15 , little is known about the regulation of this miRNA in granulopoiesis. Our data reveal novel insights into the function of miR-30c in granulocytic differentiation.
For
In summary, our study demonstrates that miR-30c plays a critical role in regulating the myeloid differentiation induced by C/EBPα ( Figure 7A ). There is strong evidence 
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For personal use only. on April 15, 2017. by guest www.bloodjournal.org From 31 For personal use only. on April 15, 2017. by guest www.bloodjournal.org From
Figure 6
